Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Thorax

Volumn 72, Issue 4, 2017, Pages 340-346

  Kolb, Martin ^a   Richeldi, Luca ^b   Behr, Jürgen ^c   Maher, Toby M ^d,e   Tang, Wenbo ^f   Stowasser, Susanne ^g   Hallmann, Christoph ^g   Du Bois, Roland M ^h  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF MUNICH   (Germany)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis

Indexed keywords

NINTEDANIB; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE;

AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; CLINICAL TRIAL; PATHOPHYSIOLOGY; QUESTIONNAIRE; TREATMENT OUTCOME;

AGED; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG VOLUME MEASUREMENTS; MALE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85017017908     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-208710     Document Type: Article

References (34)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med 2015;109:661-70.
3. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-6.
4. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.
5. Nathan SD, Shlobin OA, Weir N, et al. Long-Term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-9.
6. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014;145:579-85.
7. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
8. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9.
9. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
10. Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial. Eur Respir J 2013;42:1622-32.
11. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
12. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
13. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45.
14. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;195:e3-19.
15. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014;23:220-4.
16. National Institute for Health and Care Excellent (NICE).Pirfenidone for treating idiopathic pulmonary fibrosis. NICE technology appraisal guidance 282. Issued April 2013. http://guidance.nice.org.uk/ta282 (accessed 25 Feb 2016).
17. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across pre-specified subgroups in INPULSIS®. Am J Respir Crit Care Med 2016;193:178-85.
18. Kolb M, Richeldi L, Kimura T, et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials [abstract]. Am J Respir Crit Care Med 2015;191:A1021.
19. Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:103-10.
20. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-63.
21. Collard HR, Yow E, Richeldi L, et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013;14:73.
22. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: The INSIGHTS-IPF registry. Eur Respir J 2015;461:186-96.
23. Salisbury ML, Xia M, Zhou Y, et al. Idiopathic pulmonary fibrosis: gender-Agephysiology index stage for predicting future lung function decline. Chest 2016;149:491-8.
24. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6(Suppl 16):5-40.
25. Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: A systematic literature review. Eur Respir J 2015;46:1113-30.
26. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013;144:234-40.
27. Cottin V, Richeldi L. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev 2014;23: 106-10.
28. Thickett DR, Kendall C, Spencer LG, et al. Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: A round table discussion. Thorax 2014;69:1136-40.
29. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016;47:243-53.
30. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2093-101.
31. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
32. Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014;15:157.
33. Fang WB, Yao M, Cheng N. Priming cancer cells for drug resistance: role of the fibroblast niche. Front Biol 2014;9:114-26.
34. Crestani B, Quaresma M, Kaye M, et al. Long-Term treatment with nintedanib in patients with IPF: An update from INPULSIS-ON. Eur Respir J 2016;48(Suppl 60): OA4960.